Asad Bhatty

Cardiology trainee that likes travelling!

[Prof Chris P Gale @cpgale3]

There are feasibility factors intrinsic to a PROM, beyond its psychometric properties, that impede its routine use.

We propose the FACTOR3 checklist to evaluate the intrinsic feasibility characteristics of a PROM for trials & clinical application.

https://t.co/ds5d7OgkJC

[Diana S. Fleischman @sentientist]

In adults, limiting smartphone functionality to texting and calls and blocking all social media and mobile internet for 2 weeks significantly improved attention, self-reported well-being and mental health. 90% of participants experienced a benefit.

[Piotr Buszman MD, PhD @piotr_buszmanMD]

With great pleasure we report metaanalysis of 5 trials including LEMANS at 10 year follow-up in @JACCJournals. There is no difference in mortality between PCI and CABG for left main disease. In fact its identical : 23.4% vs 23.3%, HR 1.02 (0.89–1.17), RMST difference of exactly 0.0 years. Those are outcomes still with BMS and rare IVUS. Not bad! Great news for the patients. @GreggWStone @Hragy @SerruysPatrick @ZSiudak @EAPCIPresident @AHP_PAKS @uniwersytet_afm Thank you David Koeckerling and Ahmad Yosif.
https://t.co/Kk9cy8v11o

[Circulation @CircAHA]

#SimPub #ACC26 HEPARIN STEMI RCT: Pre-hospital UFH at first medical contact improved pre-PCI TIMI 2-3 flow without excess bleeding. Supports routine prehospital anticoagulation in STEMI referred for primary PCI. @DaniloFrancoMD https://t.co/Y1hamaaLuI

[JACC Journals @JACCJournals]

In this RCT of complex bifurcation #PCI using DK crush technique, 1-year benefits of #IVUS-guided PCI were driven by achieving IVUS optimization targets, not IVUS use alone. https://t.co/Uv1QbERUUL #JACC #ACC26

[NEJM @NEJM]

Presented at #ACC26:

Among patients with unprotected left main coronary artery disease, intravascular ultrasonography–guided PCI did not result in a lower risk of ischemic events or death than angiography-guided PCI. Full OPTIMAL trial results: https://t.co/bJ51ghVFq2

Editorial: Seeing the Left Main Coronary Artery Clearly — Is IVUS Always Necessary? https://t.co/Om82iZjnAL

@ACCinTouch

[Prof Derek Connolly @DrDerekConnolly]

Triple lipid-lowering therapy initiated at ACS hospitalization may markedly reduce cardiovascular events through earlier and more complete achievement of LDL-C targets

https://t.co/0B7OHcwfuk

@ProfKausikRay @rgiugliano @DLBHATTMD @society_eas @PCCS_UK

[NEJM @NEJM]

Original Article: Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents (ADAPT AF-DES trial) https://t.co/dv3pFDhobr

Editorial: Thromboprophylaxis for Atrial Fibrillation in Patients with Drug-Eluting Stents https://t.co/JOlf1K8Exk

#Cardiology

[Sripal Bangalore @SripalBangalore]

Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel CAD https://t.co/ECxuftCm59. @SVRaoMD @glennfishman @DFCapodanno @mmamas1973 @realarainmd @mirvatalasnag @RizikMd @sbrugaletta @drjohnm

[Mattia Galli @MattiaGalli10]

New RCT evidence supporting the clinical benefit of genotype-guided P2Y12i in ACS, with most benefit within 3 months post-PCI. In light of NEOMIND-SET, this is the only de-escalation strategy shown to reduce early post-PCI bleeding—when it matters most.

https://t.co/8sGGHUNMJl

[Prof Chris P Gale @cpgale3]

Measuring what matters, measuring well: a call to strengthen health-related quality of life patient-reported outcome measures in cardiovascular care https://t.co/z27wGy78ea

[Asad Bhatty @AsadBhatty2]

@cpgale3 And thank you to @chapdoc1 for taking it easy on me for the VIVA!

[Asad Bhatty @AsadBhatty2]

@cpgale3 Thank you @cpgale3 and Dr Chris Wilkinson for all the support over the past two years!

[Prof Chris P Gale @cpgale3]

We found only one disease-specific HRQoL instrument for AS, TASQ. However, it was ranked as having inadequate psychometric properties, therefore its patient reported data should be used with caution.

https://t.co/RtAeJ8v1ty

[Eric Topol @EricTopol]

Normalization of glucose in people with prediabetes, i.e. achieving remission, is linked to halving of major cardiovascular adverse events over ensuing decades
https://t.co/2Tb3BcoGnP

[Harlan Krumholz @hmkyale]

Do clinical trials expire?
New heart attack studies show that evidence from the 1980s may not apply to patients in 2025.
Beta blockers are a case study in how medicine evolves, and how slowly our evidence base often keeps up.
My latest Substack:
https://t.co/VuGqbqdsRq

[Colin Berry @ColinBerryMD]

Fractional flow reserve vs angiography in non-ST- elevation myocardial infarction: long-term results of the FAMOUS-NSTEMI trial | European Heart Journal | Oxford Academic https://t.co/gPXnlSssil

[Prof Chris P Gale @cpgale3]

This SR & MA of 35 studies of UK inequalities in mortality found:
⬆️relative mortality in White Irish males & White Scottish males & females
⬇️mortality in Bangladeshi, Indian, Pakistani, Black Caribbean & Chinese compared to White British
@LancetRH_Europe
https://t.co/SZ3ZwUOIu5

[Millbrook Medical Conferences @MillbrookMed]

Good morning from Eccentric Calcium! Dominic and Nat are in Liverpool, where delegates are tuned into the first Live Case of the day. Operators Liam Mullen and @ammozid are talking through the case with course director @jdinaus.

[Asad Bhatty @AsadBhatty2]

@tamimakbari1 @bp_halliday @dj_pennell @drdanhamm @DrREJones @journalofCMR @ImperialNHLI @GSTTnhs @RoyalBrompton Well done Tamim and team!